An observational study in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 19 sites in Russia. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Novartis Pharmaceuticals · Observational
ANIMA-R is an observational, prospective, non-interventional, multicenter study to assess real-world effectiveness of secukinumab in the treatment of Hidradenitis Suppurativa (HS).
The index date will be the date of secukinumab initiation. During the study, data will be collected from patients receiving routine secukinumab treatment, which is representative of the actual patient population.
The attending physician will decide whether to prescribe secukinumab based on the approved instructions for medical use in a routine clinical setting, regardless of the patient's participation in a non-interventional study.
277 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.
This study's enrollment of 107 is below the median of 142 across 69 observational studies indexed under Hidradenitis Suppurativa.
Browse Hidradenitis Suppurativa studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients with moderate to severe Hidradenitis Suppurativa commencing treatment with secukinumab
Exclusion Criteria:
Patients prescribed with secukinumab in the treatment of Hidradenitis Suppurativa
Other: Secukinumab
This is an observational study. There is no treatment allocation. The decision to initiate secukinumab will be based solely on clinical judgement.
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
The International Hidradenitis Suppurativa Severity Scoring System (IHS4) allows for a dynamic assessment of the disease severity both in clinical studies and in real-world clinical setting. The IHS4 is determined by counting nodules, abscesses, and draining tunnels (fistulae/sinuses). IHS4 (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. A score of 3 or lower indicates a mild stage of hidradenitis suppurativa, a score of 4-10 indicates a moderate stage, and a score of 11 or higher indicates a severe stage of the disease. The IHS4 severity scoring system assumes that the presence of a draining tunnel (fistula/sinus) is sufficient to classify a case as at least moderate.
Time frame: 12 months
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Proportion of patients receiving Hidradenitis Suppurativa (HS)-specific concomitant treatments in combination with secukinumab
Time frame: 12 months
Time of initiation of concomitant medication
Time of initiation of concomitant medication (before or after the initiation of secukinumab).
Time frame: 12 months
Duration of treatment with concomitant medication
Duration of treatment with concomitant medication of secukinumab
Time frame: 12 months
Number, type, and outcome of surgical interventions
Number, type, and outcome of surgical interventions (minor and major surgical excision; inpatient, outpatient, or self-treatment at home)
Time frame: 12 months
Timepoint of and reason for surgical intervention
Timepoint of and reason for surgical intervention.
Time frame: 12 months
Duration of discontinuation/pause of secukinumab treatment before surgery
Duration of discontinuation/pause of secukinumab treatment before surgery
Time frame: 12 months
Duration of discontinuation/pause of secukinumab treatment after surgery
Duration of discontinuation/pause of secukinumab treatment after surgery
Time frame: 12 months
Surgery outcome
Surgery outcome by type of wound healing, pain relief and discontinuation or continuation of secukinumab.
Time frame: 12 months
Outcome of surgery and adverse events stratified by secukinumab management
Outcome of surgery (healing, pain relief) and adverse events (i.e., infections) stratified by secukinumab management (continuation or discontinuation).
Time frame: 12 months
Predictors of treatment response
Listing of predictors of treatment response
Time frame: 12 months
Proportion of patients achieving 75% reduction in IHS4 (IHS4-75) and 100% reduction in IHS4 (IHS4-100)
The International Hidradenitis Suppurativa Severity Scoring System (IHS4) allows for a dynamic assessment of the disease severity both in clinical studies and in real-world clinical setting. The IHS4 is determined by counting nodules, abscesses, and draining tunnels (fistulae/sinuses). IHS4 (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + \[number of draining tunnels (fistulae/sinuses) multiplied by 4\]. A score of 3 or lower indicates a mild stage of hidradenitis suppurativa, a score of 4-10 indicates a moderate stage, and a score of 11 or higher indicates a severe stage of the disease. The IHS4 severity scoring system assumes that the presence of a draining tunnel (fistula/sinus) is sufficient to classify a case as at least moderate.
Time frame: Month 6, month 12
Lesion spread
Lesion spread (defined as total abscess and inflammatory nodule count (AN) or draining fistula in a body region not seen at baseline) assessed by number, type, and localization of HS lesions
Time frame: Baseline, month 6, month 12
Mean change of nodule count
Mean reduction of nodule count
Time frame: Month 6, month 12
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Novartis Pharmaceuticals